Articles tagged with Tumor Cells
Researchers have made a breakthrough in cancer treatment using nanoparticles that can be activated by radiation, resulting in statistically significant reductions in tumor size. This innovative approach builds on previous research and has the potential to effectively treat tumors throughout the body.
A non-coding region of the genome has been discovered to regulate the development of cancer in various types of tumors, including breast cancer and sarcomas. The RPSAP52 RNA molecule triggers cell proliferation and cancels differentiation, allowing tumor cells to multiply and spread.
Rhabdoid tumors are aggressive brain and kidney cancers with poor prognosis, requiring innovative treatments. The ERC grant aims to understand the disease's underlying mechanisms through unique models and lineage tracing techniques.
Researchers discovered that telomerase, which promotes unlimited cell division in cancer cells, also prevents tumors and slows a key stage in normal cell death. In healthy adult cells, telomerase activates just before cell death, buffering cells from aging stresses and reducing DNA damage.
The National Institutes of Health has granted $2.23 million in funding to develop statistical and computational methods for genome-wide CRISPR/Cas9 screening. The goal is to improve functional gene identification, analyze non-coding elements, and study genetic interactions, with potential applications in cancer research.
Researchers found that non-cancerous cells in tumor microenvironment regress into stem cell-like state, supporting cancer growth. This 'corruption' of neighboring cells enables cancer to thrive and spread.
Researchers at Mayo Clinic found that increasing PD-L1 expression in colorectal cancer cells can improve chemotherapy effectiveness. This discovery suggests a potential strategy to enhance treatment outcomes for patients with resistant colon cancer.
Researchers discovered an antibody drug that can destroy immune cells surrounding solid tumours, allowing T-cells to attack and kill cancer cells more effectively. The approach could improve treatments for various types of cancer, including CAR-T therapy.
Researchers at UC San Diego have developed a new therapeutic approach to convert tumor-associated macrophages (TAMs) into cancer killers. The antibody, LM609, induces ADCC and kills drug-resistant tumors, prolonging response to standard treatments.
Researchers at Tel Aviv University discovered that tumor cells 'hijack' an inflammatory pathway in the brain to spread melanoma, and blocking this pathway could prevent brain metastases. The study found that inhibiting the expression of a specific receptor on melanoma cells significantly inhibited the development of brain metastases.
A recent study using single-cell sequencing has revealed that glioblastoma, a deadly brain cancer, can shift among four distinct cell types, each requiring separate targeted therapy. The findings indicate a need for combination treatments and provide new insights into the cancer's plastic nature.
Researchers found that cigarette smoke changes the metabolism of cells in head and neck squamous cell carcinomas, making tumors more efficient as an ecosystem to promote cancer growth. The study also identified a protein on tobacco-exposed fibroblasts that drives these metabolic changes.
Researchers developed a novel method to directly detect circulating tumor cells in blood samples without enrichment, using lanthanide ions released from nanoparticles. The technique was tested on cancer patients' blood samples, correctly identifying 14 out of 15 cases with strong correlation to cancer stage.
Scientists at Oregon State University have discovered a protein modification that enables tumor cells to proliferate without harming healthy cells. This finding opens up new avenues for cancer therapies with minimal side effects.
Researchers have identified a contagious form of cancer in dogs, known as CTVT, which has persisted for thousands of years. The study reveals that cancer cells can evolve and stabilize over time, offering new insights into human cancer development and treatment.
Researchers at Worcester Polytechnic Institute developed a chip made of carbon nanotubes that captures circulating tumor cells (CTCs) with far greater sensitivity than existing technologies. The device can detect early-stage tumors, predict the course of a cancer, and monitor the effects of therapy.
The fruit fly Drosophila melanogaster produces more Defensin, which interacts with dying tumour cells and kills them, while sparing normal cells. This finding reveals an anti-tumour role for Defensin and provides insights into the molecular mechanisms behind AMPs' killing action.
Researchers discovered that natural killer (NK) cells can express PD-L1 and provide anti-tumor activity when treated with checkpoint inhibitors. PD-L1+ NK cells can control tumor growth by killing tumors and secreting cytokines, providing a new immunotherapeutic avenue.
Researchers found a common vulnerability among aneuploid cancer cells, which are bloated and overstuffed due to high intracellular protein concentrations. The team identified a molecular pathway involving proteins ART1 and Rsp5 that regulates nutrient uptake in these cells.
Researchers at Hokkaido University have discovered how a protein called Epe1 maintains a balance between tightly packed and variable DNA structures in yeast cells. This finding could lead to new strategies for suppressing the formation of tumor cells resistant to anti-cancer drugs.
Research conducted at the Irvine Lab at MIT's Koch Institute showed that activation of CAR-T cells in lymph nodes leads to massive CAR-T cell expansion and significant functional improvements. The AMP-CAR-T Platform combines CAR-T therapy with Amphiphile immunotherapies to amplify immune responses and combat solid tumors.
A new potential therapeutic target has been identified for oesophageal cancer treatment. MAIT cells, a lesser-known type of immune cell, have been found to have potent cancer-killing ability.
Scientists at IDIBELL-ICO describe a novel mechanism of resistance to therapies that prevent blood vessel formation, which involves immune cells acting as tumor malignant elements. The study highlights the importance of targeting Sema4D and its secretion by macrophages to inhibit this mechanism.
Researchers have developed a genetically modified virus that kills cancer cells and makes them sensitive to chemotherapy drugs, halting tumor progression in mice. The combination of p53 gene therapy and cabazitaxel resulted in full control of tumor growth, with an additive or synergistic effect.
Researchers at the University of Pennsylvania School of Medicine have identified a protein called TOX as the key regulator of exhausted immune cells in cancer. The discovery could lead to new immunotherapies that target or engineer TOX to reverse exhaustion and improve immunity to infections or cancer.
Researchers found that regular cells can adopt immune cell characteristics, sending warning signs when stressed or in danger. This mechanism may aid in detecting cancer cells sooner, preventing tumor formation.
A high salt diet has been shown to inhibit tumor growth in mice by altering the function of certain immune cells called myeloid-derived suppressor cells. This effect could be beneficial for improving anti-cancer immunotherapies, but further research is needed to fully understand its therapeutic potential.
Researchers discovered a molecular mechanism that allows cancer cells to regenerate and evade therapy, but found treatments that can target these cells. The study provides a new logic for identifying therapies that can kill hard-to-kill cancer cells.
Researchers found that immune cells recruited by tumor cells drive faster growth, suggesting targeting immune system cells could slow brain tumor growth in people with neurofibromatosis type 1 (NF1). The study suggests reprogramming T cells to shut down tumors, a promising new strategy for treating NF1.
A study found that pancreatic cancer cells can behave differently based on their surroundings, with some responding better to chemotherapy and radiation. The stroma of tumors consists of connective tissue cells that contribute to tumor growth and spread.
A human enzyme named FANCM is essential for the survival of cancer cells using an alternative telomere lengthening pathway. ALT tumor cells require FANCM activity to prevent telomere instability and cell death.
A molecule called LL-37 has been found to boost the function of dendritic cells, which are used in cancer therapy. This improvement could lead to more effective treatments by increasing the success rate of dendritic cell-based therapies.
Research at Technical University of Munich shows that molecular chaperones Hsp70 and Hsp40, as well as Hsp90, control the function of p53 by influencing its three-dimensional structure. This helps prevent cancer cells from growing.
Researchers at VCU Massey Cancer Center have made a significant discovery regarding tumor dormancy, a state of inactivity that allows cancer cells to evade detection and recurrence. By targeting senescent cells, they hope to develop novel therapeutics that can eliminate dormant tumor cells and prevent disease recurrence.
Researchers have developed a new technique called BiGluc, which enables the visualization of glucose metabolism in real-time in cancerous tumors. This non-invasive imaging method could lead to more effective cancer treatments by identifying the metabolic requirements of different tumors.
Researchers at University of Helsinki found that MDGI protein plays a key role in regulating lysosomal membrane stability. Inhibiting this protein causes glioblastoma cell death, particularly with antihistamine clemastine, which can cross the blood-brain barrier.
Researchers have engineered molecules that restrict access to heme, an oxygen-binding molecule, to slow the growth of lung cancer tumors in mice. By starving cancer cells of this essential molecule, the new approach may provide a potential new path forward in treating non-small cell lung cancer.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
Researchers at Salk Institute uncover role of signaling protein LIF in pancreatic cancer development and progression, suggesting it may be a useful biomarker for earlier diagnosis and more effective therapies. Elevated LIF levels were significantly correlated with tumor cell status and response to chemotherapy.
Researchers at McMaster University have discovered a unique subset of cells, called human pluripotent founder cells, that appear to signal how surrounding cells will develop and grow. These 'kingpin' cells are found in primates but not in mice, suggesting they may play a key role in understanding cancerous tumours.
Researchers analyzed methods of targeted drug delivery to malignant tumors, exploring passive targeting, active targeting, and cell-mediated targeting. By understanding tumor structure and metabolism, scientists can develop personalized treatment approaches to increase efficiency and reduce side effects.
New research shows that magnetic hyperthermia therapy is tunable depending on nanoparticle diameter and material composition. The study demonstrates increased tumour absorption rates as particle diameter increases, offering new avenues for targeted cancer treatment.
A phase I clinical trial combining telomelysin and radiotherapy achieved an impressive 85% overall response rate (ORR) and complete tumor eradication in most patients. The therapy was safe and effective, even for elderly patients with health complications.
Scientists have found that successful removal of breast cancer tumors triggers a strong immune response, which clears disseminated tumor cells from lymph nodes and organs. In contrast, leaving behind primary tumor cells supports tumor growth and metastasis.
Breast cancer cells are inherently changeable, morphing from one cell type to another at the molecular level. This feature may promote resistance to certain therapies. The research provides new insights into how cancer cells develop and evolve within tumours.
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
The study shows that Wt1 gene deletion causes deterioration of the pancreas and activates stellate cells, which play a key role in pancreatic cancer progression. The results suggest Wt1 gene is necessary for normal pancreas maintenance and repair after damage.
University of Otago scientists have developed a method to analyze the diversity of immune cells within bowel cancer tumours. This breakthrough could lead to more targeted treatments and improved patient outcomes.
A new study suggests that consuming thermally abused cooking oil may trigger genetic changes that promote the progression of late-stage breast cancer. Mice fed thermally abused oil developed more tumors and aggressive growth than those fed fresh soybean oil, highlighting a potential link between diet and cancer recurrence.
A team of researchers has created a detailed 'atlas' of cell states for acute myeloid leukemia (AML), a type of aggressive cancer. The atlas, generated using single-cell genomics and machine learning, identifies distinct cell types and their genetic characteristics, shedding light on the disease's heterogeneity.
A research team has assembled a detailed atlas of bone marrow cells from AML patients, revealing six stages of white blood cell development and a role for differentiated tumor cells in suppressing immune responses. The study may lead to personalized therapies targeting specific AML cell types.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients
Researchers at the University of California San Diego discovered that breast tissue stiffening triggers multiple pathways to promote cancer cell formation. The study, published in PNAS, found that a subpopulation of mammary cells do not respond to stiffening, potentially leading to fewer or smaller primary tumors.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
The foundation awarded grants to nine early-career scientists working on novel approaches to fighting cancer. The recipients will receive up to four years of funding to explore their projects, which include gene editing technology CRISPR and single cell sequencing techniques.
Researchers discovered that STAT5B facilitates leukemogenesis in B-cell acute lymphocytic leukemia. They found that the absence of STAT5B increases interferon response and suppresses transformation. This understanding may enable precision medicine strategies to treat disease.
Researchers have engineered immune cells to target different types of pediatric solid tumors, including brain tumors, with promising results. The treatment uses a surface marker called B7-H3, which is expressed on most pediatric cancer cells, and has been shown to eradicate tumors in mice.
Researchers propose a new perspective on cancer origins, highlighting the importance of mutation sequence and cell type in tumor growth and response to therapy. This approach may lead to new avenues for cancer prevention and treatment.
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.